Ado-trastuzumab

【Product name】Kadcyla

[English common name]Ado-trastuzumab emtansine

[Chinese common name]Ado-trastuzumab

[English name]

[Chinese other name]

[indications] metastaticBreast cancer: This product is suitable for HER2-positive metastatic breast cancer: metastatic breast cancer that has received one or more chemotherapy regimens as a single drug; combined with paclitaxel or docetaxel for metastasis without chemotherapy Breast cancer patients.
Adjuvant therapy for breast cancer: This product is suitable for the adjuvant treatment of HER2 overexpressing breast cancer after surgery, adjuvant chemotherapy with anthracyclines and radiotherapy (if applicable).
Metastatic gastric cancer: This product is combined with capecitabine or 5-fluorouracil and cisplatin for patients with metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have not received HER2 overexpression for the treatment of metastatic disease.
Trastuzumab can only be used in patients with metastatic gastric cancer with HER2 overexpression, and HER2 overexpression is defined as IHC3+ or IHC2+/FISH+ results obtained using validated assays.

[Usage and Dosage] Please fully dilute the reconstituted drug after the requirement of 'infusion preparation'.
Do not push or push the vein quickly.
HER2 testing should be performed prior to treatment with this product.
The use of any other biological substitutes requires the consent of the prescribing physician.
This product should be administered by intravenous infusion.
Metastatic breast cancer
Weekly dosing schedule
Initial load dose: It is recommended that the initial load of this product is 4mg/kg. Intravenous infusion for more than 90 minutes.
Maintenance dose: This product is recommended to be used at a dose of 2 mg/kg per week. If the initial load is tolerable, the dose can be infused intravenously for 30 minutes. Maintain treatment until disease progression.

[Storage] Store in the refrigerator (2 ° C – 8 ° C).

[Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

Description

name

Attention: The internal data of table “67” is corrupted!

product

Attention: The internal data of table “68” is corrupted!

product manual

Click to view ado-trastuzumab English product description

Click to view ado-trastuzumab Chinese product description

Product information

Click to view ado-trastuzumab English product information

Click to view ado-trastuzumab English product specifications

Related products

  • Breast cancer , Renal cell carcinoma (RCC)

    Sorafenib

    【Product name】NEXAVAR

    [English common name]Sorafenib

    [Chinese common name]Sorafenib

    [English name]

    [Chinese other name]Solafini, sorafini monomer

    [indications]
    Sorafenib: TYKERB lapatinib is used in combination with capecitabine to treat ErbB-2 overexpression and has previously received advanced or metastatic treatments including anthracyclines, paclitaxel, and trastuzumab (Herceptin). SexBreast cancer.
    Sorafenib tosylate tablets: treatment of advanced surgeryRenal cell carcinoma.
    Nexavar (Sorafenib): Sorafenib has been approved for the treatment of advanced renal cell carcinoma (the most common type of kidney cancer). In addition, there are currently nearly 50 clinical trials in the world that use sorafenib to treat a variety of other cancers.

    【Dosage】
    Sorafenib: The recommended dose is 1250 mg, once a day, on days 1 to 21, with capecitabine 2000 mg/d, and on the first to 14 days in 2 divided doses. Lapatinib should be taken once a day. It is not recommended to take it in divided doses. Take 1 h before meals or 2 h after meals. If one dose is missed, the dose will not be doubled on the second day. Pregnancy level D, pregnant women are banned. It is unclear whether milk secretion is passed, and lactating women should stop breastfeeding. There were no significant differences between the elderly and young patients. Patients with severe kidney damage and dialysis have not been clinically tested, and patients with moderate to severe liver damage should be given a dose reduction.
    Sorafenib tosylate tablets:
    Recommended Dosage: It is recommended to take sorafenib for 0.4 g (2 x 0.2 g) each time, twice daily, on an empty stomach or with a low-fat, medium-fat diet.
    How to use: Oral, swallow with a cup of warm water.
    Treatment time: The treatment should be continued until the patient is unable to clinically benefit or tolerate the toxic reaction.
    Nexavar (Sorafenib): Patients should read the product instructions and patient instructions carefully before taking the drug. Patients should be advised to take effective contraception during the medication and to try to conceive after at least 2 weeks of discontinuation. Inform patients to take the medicine on an empty stomach. If the patient forgets to take the medicine, there is no need to increase the dose for the next dose. When the patient has a rash on the hands and feet during the medication, he should contact the doctor for treatment accordingly.

    [Storage]
    Sorafenib tosylate tablets: Store at a temperature below 25 ° C. Keep the drug out of the reach of children.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer

    Lapatinib

    【Product name】Tykerb

    [English common name]Lapatinib

    [Chinese common name]Lapatinib

    [English name]4-Quinazolinamine, lapatinib ditosylate monohydrate, GSK572016

    [Chinese other name]Lapatinib base, lapatinib dimethanesulfonate intermediate, lapatinib monomer

    [Indications] TYKERB lapatinib is used in combination with capecitabine for the treatment of ErbB-2 overexpression, and has previously received advanced or metastatic treatment including anthracyclines, paclitaxel, and trastuzumab (Herceptin).Breast cancer.

    [Usage and Dosage] The recommended dose is 1 250 mg once a day, taken on the 1st to 21st day, combined with capecitabine 2 000 mg/d, and taken in 1 to 14 days. Lapatinib should be taken once a day. It is not recommended to take it in divided doses. Take 1 h before meals or 2 h after meals. If one dose is missed, the dose will not be doubled on the second day. Pregnancy level D, pregnant women are banned. It is unclear whether milk secretion is passed, and lactating women should stop breastfeeding. There were no significant differences between the elderly and young patients. Patients with severe kidney damage and dialysis have not been clinically tested, and patients with moderate to severe liver damage should be given a dose reduction.

    [Storage] Do not store above 30oC.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer

    Pabista

    【Product name】Farydak

    [English common name]Panobinostat

    [Chinese common name]Pabista

    [English name]LBH-589

    [Chinese other name]

    [Indications] Farydak is combined with bortezomib and dexamethasone for the treatment of relapse and / or refractoryMultiple myelomaAdult patients who have received at least two treatment regimens, including bortezomib and immunomodulators.

    [Usage and Dosage] 20mg orally, once a day, three times a week, two weeks off each cycle for one week.

    [Storage] Do not store above 30 °C. Store in original packaging to protect it from moisture.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.

  • Breast cancer , Myelodysplastic syndrome

    Azacitidine

    【Product name】VIDAZA 

    [English common name]Azacitidine

    [Chinese common name]Azacitidine

    [English name]

    [Chinese other name]

    [indications]Acute non-lymphocytic leukemia. Used forBreast cancer,Intestinal cancer,MelanomaWait for a certain effect.

    [Usage and dosage] 100mg/m2, intravenous bolus injection, once every 8 hours, for 5 days, 200mg / (m2 · d) intravenous infusion, for 5 days.

    [Storage] Vidaza should be re-injected with water. The shelf life of the reconstituted drug can be extended by reinjection with frozen (2 ° C to 8 ° C) water.

    [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.